Articles in Press Artikel

Choosing and Developing User-friendly Osmotic Laxatives for a More Patient-centric Portfolio

Oct 09, 2022

Constipation is a widespread and growing issue. But most laxative treatments fail to adequately meet patient needs, being unpleasant to take and causing significant side effects. The solution lies in simple, flexible, user-friendly alternatives that put patients first. However, pharmaceutical companies looking to incorporate these alternatives into their portfolio must overcome several formulation and manufacturing challenges. Article in International Pharmaceutical Industry.

How macrogols overcome the drawbacks of other laxatives to deliver a user-friendly, effective constipation treatment

At least 1 in 10 people worldwide will suffer from constipation in their lifetime. And the incidence is only set to grow. While timely treatment in the form of laxatives is essential, most laxatives have significant side-effects and are unpleasant to take.

For a patient-centric, successful portfolio, pharmaceutical companies need products that minimize side-effects and are easy to use. In this article published in International Pharmaceutical Industry (pp 67 ff, vol. 14 Issue 2, 2022), experts Dr Martin Koeberle and Dr Verena Garsuch discuss:

The prevalence and causes of constipation
The significant drawbacks of many laxatives
Macrogols as a simple, safe, and user-friendly treatment
The formulation and manufacturing hurdles companies must overcome to make macrogols part of their portfolio

DOWNLOAD ARTICLE (PDF)

Back